Rexam Healthcare receives Lilly award

2010 Lilly Global Supplier Award recognises positive impact made on quality, speed and service

Rexam Healthcare, a global leader in healthcare packaging and devices, has been awarded a 2010 Lilly Global Supplier Award in recognition of its positive impact on Lilly in the areas of quality, speed, service and cost reduction.

‘We have demonstrated our capacity to manage a large-scale industrial project in close partnership with Lilly and to create value with high-quality solutions and support services, for the entire benefit of diabetic patients throughout the world,’ said Marc Haemel, managing director of Rexam Healthcare.

‘We are proud of our teams for this achievement and will strive to improve further the value we bring to Lilly.’

You may also like

Manufacturing

Novo Nordisk plans Ireland expansion to manufacture oral Wegovy for global markets

The company is preparing to scale production capacity at its Athlone facility as strong US uptake of its oral obesity therapy supports a broader strategy to expand global supply and compete in the fast-growing GLP-1 market
Finance

Eli Lilly becomes first $1 trillion pharma company

Fuelled by the GLP-1 boom, the drugmaker's stock has surged by more than 35% this year, with the company reaching a $1 trillion valuation on Friday — becoming the first pharmaceutical company ever to achieve the milestone
Finance

Weight loss drugs fuelling rapid big pharma growth, report reveals

Weight loss and diabetes medications are championing growth in key big pharma players, such as Novo Nordisk and Eli Lilly
Manufacturing

Eli Lilly to expand US pharma manufacturing capabilities with four new sites

The company's four new pharmaceutical manufacturing sites will produce active pharmaceutical ingredients (APIs), while also boosting the company's small molecule chemical synthesis and injectable manufacturing capabilities
Packaging

Nemera's UniSpray compatible with Nipro's unit-dose microvials

Nipro PharmaPackaging and Nemera announce the successful compatibility testing of Nemera’s UniSpray and Nipro’s unit-doseTM microvials
Drug Delivery

Eli Lilly to leverage ViaNautis Bio's nanovesicle technology for genetic medicine development

ViaNautis' polyNaut nanovesicles can deliver genetic materials to specific tissues or cell types, allowing for more accurate therapeutic targeting
Research & Development

Eli Lilly to buy bowel biopharma company Morphic

The USD $3.2bn deal will boost Eli Lilly’s offerings for patients with inflammatory bowel disease, including a number of Phase II therapeutic candidates
Subscribe now